AGENDA

Enclosure

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Chairman’s report (verbal update)
5. Minutes of previous meeting
6. Appraisal 1
   *Racecadotril (Hidrasec®)* granules for oral suspension for the complementary symptomatic treatment of acute diarrhoea in infants (older than 3 months), and in children, together with oral rehydration, and the usual support measures, when these measures alone are insufficient to control the clinical condition
7. Appraisal 2
   *Vildagliptin (Galvus®)* for the treatment of type 2 diabetes as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance
8. Appraisal 3
   *C1 inhibitor (Cinryze®)* for the treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE) and for routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment
9. Appraisal 4
   *Insulin glargine (Lantus®)* for the treatment of diabetes mellitus in children aged 2 to less than 6 years
10. Monitoring of medicines appraised by AWMSG / NICE
11. National Prescribing Indicators 2012-2013
   Analysis of prescribing data to September 2012
   7/AWMSG/0213

12. Pharmacy teaching in Wales
   8/AWMSG/0213

13. All Wales guidance for prescribing gluten free products
   9/AWMSG/0213

14. All Wales review and guidance for prescribing intervals
    (28-day prescribing)
   10/AWMSG/0213

15. Date of next meeting:
    Wednesday 20th March 2013 in Abergavenny